



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

Uscom Earnings Call Half-year financial results to 31 December 2014

Sydney, Australia: Thursday, 19th February 2015: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical technology company, will hold a conference call to discuss the company's financial results for the Half-year ended 31 December 2014, and its business outlook. Dr Rob Phillips, Executive Chairman will host the call.

The Company will file its Appendix 4D with the ASX on Tuesday, 24th of February, 2015 (AEST). The briefing call to discuss financial results and business update will be held at 12pm. AEST on Thursday, 26th February, 2015.

Accessing the Briefing Call via Telephone:

Please dial in five minutes prior to the start of the call and provide the pin number 3175198. Regional dial-in numbers are as follows:

- **Sydney:** 02 9007 4041
- **Melbourne:** 03 9912 0327
- **Brisbane:** 07 3107 0200
- **Australia:** toll-free 1800 556264
- **International:** +61 2 9007 4041

Replay archive:

The audiocast will be archived for 30 days following the call on the Uscom website at www.uscom.com.au.

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure and hypertension, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is emerging as the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms, measures otherwise only available by cardiac catheterisation, using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Dr Rob Phillips
Executive Chairman
rob@uscom.com.au

Catherine Officer
Company Secretary
secretary@uscom.com.au